RCM-1 is an inhibitor of FOXM1.

RCM-1 inhibits cellular proliferation via the increasing duration of cell cycle and mitosis in human and mouse cancer cell lines in vitro. RCM-1 inhibits colony formation of cancer cells in vitro in a dose-dependent manner. RCM-1 inhibits the migration of cancer cells in vitro in a dose-dependent manner. RCM-1 inhibits the initiation as well as the growth of cancer cell colonies in vitro. Treatment with RCM-1 increases the duration of mitosis and cell cycle in the cancer cell lines [1].

RCM-1 decreases the B 16-FlO tumor growth as compared to the Vehicle -treated group. RCM-1 treatment decreases tumor cell proliferation and increased apoptosis in B16-FlO melanoma tumors. RCM-1 treatment reduces the growth of the human H2122 lung adenocarcinoma in mice. RCM-1 treatment reduces tumor cell proliferation and increases apoptosis in Rd76-9 rhabdomyosarcoma tumors. RCM-1 treatment decreases the growth of Rd76-9 rhabdomyosarcomas in mice. The RCM-1-treated Rd76-9 tumors display reduced FOXM1 staining and decreased expression of proliferation-specific markers Ki67 and PH3. Cleaved caspase staining is increased in the RCM-1 treated tumors, indicating an increase in apoptosis. RCM-1 treatment reduces the growth of B16-FlO melanoma tumors in mice [1].